Line design

Abbreviated New Drug Applications and 505(b)(2) Applications

This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.

Reference Listed Drug ANDA Holder Generic Drug Name ANDA Applicant(s) Indication Launch Date
Zyprexa Cheplapharm olanzapine Glenmark Used to treat schizophrenia and bipolar disorder. 7/6/2026
Diazepam RegCon diazepam Hikma Used to manage anxiety disorders or for short-term relief of symptoms of anxiety; to relieve symptoms in acute alcohol withdrawal; as a premedication for relief of anxiety in patients undergoing surgical procedures or cardioversion. 7/8/2026
Bridion Merck sugammadex B. Braun Used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. 7/14/2026
Janumet XR Merck sitagliptin / metformin Par Used to improve glycemic control in adults with type 2 diabetes mellitus. 7/24/2026
Bridion Merck sugammadex Par Used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. 7/29/2026
Bridion Merck sugammadex Camber  Used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. 7/30/2026
Requip XL Glaxo ropinirole Elite Used to treat Parkinson's disease. 8/4/2026
Jynarque Otsuka tolvaptan Apotex Used to slow the progression of kidney decline in adults at risk of rapidly progressing ADPKD. 8/6/2026
Retin-A  Bausch tretinoin Alembic Used to treat acne. 8/12/2026
Biaxin AbbVie clarithromycin Solaris Used to treat bacterial infections. 8/13/2026
Copaxone Teva glatiramer acetate Upsher-Smith Used to treat adult patients with relapsing forms of multiple sclerosis. 8/20/2026
Jynarque Otsuka tolvaptan Teva Used to slow the progression of kidney decline in adults at risk of rapidly progressing ADPKD. 8/27/2026
Advair Diskus Glaxo fluticasone / salmeterol Aurobindo Used to prevent asthma attacks and to treat chronic obstructive pulmonary disease (COPD).  8/31/2026
Rimso-50 Mylan dimethyl sulfoxide Renova Used to treat symptoms of interstitial cystitis (painful bladder syndrome). 9/10/2026
Nudexta Otsuka dextromethorphan / quinidine sulfate Teva  Used to treat pseudobulbar affect (PBA). 9/16/2026
Somatuline Depot Ipsen lanreotide Amneal Used to treat acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. 9/18/2026
Gilenya Novartis fingolimod Alembic Used to treat relapsing forms of multiple sclerosis. 9/22/2026

GENERICally Speaking Hatch Waxman Bulletin

Jump to Page

Robins Kaplan LLP Cookie Preference Center

Your Privacy

When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use Cookies, please see our Privacy Policy.

Strictly Necessary Cookies

Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.

Functional Cookies

Always Active

Some functions of the site require remembering user choices, for example your cookie preference, or keyword search highlighting. These do not store any personal information.

Form Submissions

Always Active

When submitting your data, for example on a contact form or event registration, a cookie might be used to monitor the state of your submission across pages.

Performance Cookies

Performance cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.

Powered by Firmseek